

4. A compound according to any one of claims 1 – 3 or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 and one or more pharmaceutically acceptable carriers, diluents or excipients.
6. A combination pharmaceutical product comprising a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 together with one or more other therapeutically active agents.
7. A compound or a pharmaceutically acceptable salt thereof as defined in claim 4 for use in therapy.
8. A compound or a pharmaceutically acceptable salt thereof as defined in claim 4 for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
9. A compound according to claim 8, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.
10. A compound according to claim 8, wherein the disease or condition is cancer.
11. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
- ~~12. A method of treating diseases or conditions for which a bromodomain inhibitor is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof as defined in claim 4.~~
- 13~~12~~. ~~A method of treatment~~The use according to claim ~~4~~11, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.
- 14~~13~~. ~~A method of treatment~~The use according to claim ~~4~~11, wherein the disease or condition is cancer.
- 15~~14~~. ~~A method of treatment~~The use according to any one of claims ~~12–11~~11 – 14 in which the subject is a human.